10x Genomics Q4 Beats Estimates, Narrows Loss to $0.13; Shares Jump 10.5%
10x Genomics reported Q4 revenue of $166 million, flat year-over-year but beating estimates, and narrowed its GAAP loss to $0.13 per share versus forecasts of a $0.21 loss. Improved cost management boosted operating margin to negative 11.8% from –30.2%, driving a 10.5% stock rally.
1. Strong Q4 Financial Performance
10x Genomics delivered Q4 revenue of $166 million, flat year-over-year but surpassing analyst expectations. The GAAP loss narrowed to $0.13 per share, outperforming the consensus $0.21 loss per share.
2. Margin Improvement Drives Profitability
Cost management initiatives reduced operating margin to negative 11.8%, a marked improvement from –30.2% a year earlier. This 18.4 percentage point improvement underpinned stronger bottom-line results.
3. Stock Reaction and Outlook
Shares surged 10.5% following the earnings announcement as investors reacted to the better-than-expected results. Management maintained a full-year revenue outlook of approximately $612.5 million, in line with market forecasts.